American Association for Cancer Research
21598290cd140295-sup-128875_2_supp_0_nh1n2q.pdf (12.06 kB)

Supplementary Figure Legends from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma

Download (12.06 kB)
journal contribution
posted on 2023-04-03, 20:40 authored by Benchun Miao, Zhenyu Ji, Li Tan, Michael Taylor, Jianming Zhang, Hwan Geun Choi, Dennie T. Frederick, Raj Kumar, Jennifer A. Wargo, Keith T. Flaherty, Nathanael S. Gray, Hensin Tsao

Supplementary Figure Legends



BRAFV600E is the most common oncogenic lesion in melanoma and results in constitutive activation of the MAPK pathway and uncontrolled cell growth. Selective BRAF inhibitors such as vemurafenib have been shown to neutralize oncogenic signaling, restrain cellular growth, and improve patient outcome. Although several mechanisms of vemurafenib resistance have been described, directed solutions to overcome these resistance lesions are still lacking. Herein, we found that vemurafenib resistance can be (i) mediated by EPHA2, a member of the largest receptor tyrosine kinases (RTK) subfamily erythropoietin-producing hepatocellular (EPH) receptors, and (ii) associated with a greater phenotypic dependence on EPHA2. Furthermore, we developed a series of first-in-class EPHA2 inhibitors and show that these new compounds potently induce apoptosis, suppress viability, and abrogate tumorigenic growth of melanoma cells, including those that are resistant to vemurafenib. These results provide proof of concept that RTK-guided growth, and therapeutic resistance, can be prospectively defined and selectively targeted.Significance: In this study, we show that resistance to selective BRAF inhibitors can be mediated by the RTK EPHA2. Furthermore, direct targeting of EPHA2 can successfully suppress melanoma growth and mitigate therapeutic resistance. Cancer Discov; 5(3); 274–87. ©2014 AACR.See related article by Paraiso et al., p. 264This article is highlighted in the In This Issue feature, p. 213

Usage metrics

    Cancer Discovery



    Ref. manager